<p>/PRNewswire/ -- 根據 Mordor Intelligence 的報告，全球伴隨診斷市場在 2025 年的估值為 87 億美元，預計到 2030 年將超過 156.2 億美元，預測期內（2025–2030 年）年均增長率為 12.42%。市場主要受精準醫療在腫瘤學和罕見疾病中的應用增長，以及基於生物標誌物的檢測需求增加的推動，以提高藥物的有效性和安全性。</p>
<p><strong>區域細分洞察</strong></p>
<p><strong>北美</strong> 繼續主導伴隨診斷市場，得益於強大的製藥管道、良好的報銷政策以及分子檢測技術的早期採用。該地區 FDA 對藥物和診斷共同開發的監管明確性也簡化了商業化路徑。</p>
<p><strong>亞太地區</strong> 正在成為增長最快的地區，受癌症負擔增加、基因檢測服務擴展以及中國、日本和印度本地化診斷解決方案快速發展的推動。國家層面的精準醫療整合到醫療系統的倡議進一步增強了區域需求。</p>
<p><strong>塑造市場動態的主要趨勢</strong></p>
<p><strong>對精準和靶向療法的需求上升</strong></p>
<p>對個性化醫療的日益重視正在重塑治療範式。製藥公司越來越依賴伴隨診斷來根據基因或分子特徵識別患者亞組。這一趨勢在腫瘤學中尤為明顯，伴隨診斷指導靶向療法的使用，如 EGFR、HER2 和 PD-L1 抑制劑。</p>
<p><strong>下一代測序（NGS）技術的整合</strong></p>
<p>基於 NGS 的檢測平台正在改變我們發現生物標誌物和進行多重檢測的方式。通過實現對多種突變的全面基因組分析，NGS 有助於減少週轉時間和每個樣本的成本。這項技術也正在超越腫瘤學，在傳染病、神經學和心血管研究中找到新的應用。</p>
<p><strong>製藥公司與診斷開發商之間的戰略合作</strong></p>
<p>製藥和診斷公司越來越多地形成戰略聯盟，以共同開發伴隨診斷與藥物管道。這些合作有助於協調監管提交，加快市場進入時間。此外，AI 和生物信息學工具的整合正在改善複雜基因組數據的解讀，支持更快的臨牀決策。</p>
<p><strong>綜合細分概述</strong></p>
<p><strong>按技術</strong></p>
<ul>
<li>聚合酶鏈反應（PCR）</li>
<li>免疫組化（IHC）</li>
<li>實時 PCR（RT-PCR）</li>
<li>原位雜交（ISH）</li>
<li>下一代測序（NGS）</li>
<li>其他技術</li>
</ul>
<p><strong>按適應症</strong></p>
<ul>
<li>肺癌</li>
<li>乳腺癌</li>
<li>結直腸癌</li>
<li>白血病</li>
<li>黑色素瘤</li>
<li>胃癌</li>
<li>前列腺癌</li>
<li>其他適應症</li>
</ul>
<p><strong>按產品和服務</strong></p>
<ul>
<li>檢測和試劑盒</li>
<li>儀器和分析儀</li>
<li>軟件和服務</li>
</ul>
<p><strong>按樣本類型</strong></p>
<ul>
<li>組織活檢</li>
<li>液體活檢</li>
<li>細胞學塗片</li>
</ul>
<p><strong>按最終用户</strong></p>
<ul>
<li>製藥和生物技術公司</li>
<li>臨牀參考實驗室</li>
<li>合同研究組織（CRO）</li>
<li>醫院和癌症中心</li>
</ul>
<p><strong>按地區</strong></p>
<ul>
<li>北美</li>
<li>歐洲</li>
<li>亞太地區</li>
<li>中東和非洲</li>
<li>南美</li>
</ul>
<p><strong>有關市場規模、細分數據和競爭情報的完整信息，請訪問 Mordor Intelligence 報告的詳細信息：</strong></p>
<p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
<p><strong>戰略市場格局</strong></p>
<p>伴隨診斷市場適度集中，全球診斷製造商、生物技術公司和技術提供商積極推進共同開發合作伙伴關係和多重檢測解決方案。市場領導者專注於在多個癌症適應症中擴展伴隨檢測，並投資於獲得監管批准的 NGS 面板。</p>
<p><strong>領先的伴隨診斷公司</strong></p>
<ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
<p><strong>查看 Mordor Intelligence 發佈的相關報告：</strong></p>
<p><strong>腫瘤分子診斷市場</strong>：腫瘤分子診斷市場報告按產品類型（儀器）、技術（聚合酶鏈反應）、癌症類型（乳腺癌）、樣本類型（組織活檢等）、最終用户（醫院）和地區（北美、歐洲、亞太地區、中東和非洲、南美）進行細分。</p>
<p>Illumina、QIAGEN、Roche、Thermo Fisher Scientific 和 Danaher 是該市場的主要公司。</p>
<p><strong>瞭解更多活躍於</strong> <strong>腫瘤分子診斷</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
<p><strong>伴隨動物診斷市場</strong>：伴隨動物診斷市場報告將行業細分為按動物（貓、狗、其他動物）、按應用（細菌學、寄生蟲學、臨牀病理學、其他應用）、按技術（免疫診斷測試、分子診斷、診斷成像、其他診斷）和地區（北美、歐洲、亞太地區、中東和非洲、南美）。</p>
<p>Heska、Neogen、Zoetis、IDEXX 和 Innovative Diagnostics 是該市場的主要公司。</p>
<p><strong>瞭解更多活躍於</strong> <strong>伴隨動物診斷</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
<p><strong>解剖病理市場</strong>：解剖病理市場報告按產品和服務（儀器、耗材和服務）、應用（疾病診斷、藥物發現與開發及其他應用）、最終用户（醫院、診斷實驗室）、地區（北美、歐洲、亞太地區、中東和非洲、南美）進行細分。</p>
<p>賽默飛世爾科技、Quest Diagnostics、羅氏、LabCorp 和安捷倫科技是該市場的主要公司。</p>
<p><strong>瞭解更多關於活躍於</strong> <strong>解剖病理學</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
<p><strong>關於 Mordor Intelligence：</strong></p>
<p>Mordor Intelligence 是一家值得信賴的合作伙伴，為尋求全面和可操作市場情報的企業提供服務。我們的全球覆蓋、專業團隊和量身定製的解決方案使組織和個人能夠做出明智的決策，駕馭複雜的市場，實現戰略目標。</p>
<p>Mordor Intelligence 擁有超過 550 名領域專家和遍佈 150 多個國家的現場專家，對全球商業環境有獨特的理解。這種專業知識轉化為涵蓋航空航天與國防、農業、動物營養與健康、自動化、汽車、化學與材料、消費品與服務、電子、能源與電力、金融服務、食品與飲料、醫療保健、酒店與旅遊、信息與通信技術、投資機會和物流等廣泛行業的綜合性綜合和定製研究報告。</p>
<p><strong>如有任何諮詢，請聯繫：</strong></p>
<p>[email protected]</p>
<p>https://www.mordorintelligence.com/contact-us</p>
<p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
<p>來源：Mordor Intelligence Private Limited</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx"/></p>

Ultragenyx制藥

<p>全球伴隨診斷市場預計將從 2025 年的 87 億美元增長到 2030 年的 156.2 億美元，年均增長率為 12.42%，主要受精準醫療在腫瘤學和罕見疾病應用的推動。北美市場領先，而亞太地區是增長最快的區域。主要趨勢包括對靶向療法需求的增加、下一代測序技術的整合，以及製藥公司與診斷公司之間的戰略合作。主要參與者包括 Qiagen、安捷倫科技和羅氏</p>

<p>, /PRNewswire/ -- According to Mordor Intelligence, the global companion diagnostics market is valued at USD 8.70 billion in 2025 and is projected to surpass USD 15.62 billion by 2030, growing at a CAGR of 12.42% during the forecast period (2025–2030). The market is primarily driven by the growing applications of precision medicine in oncology and rare diseases, and the increasing need for biomarker-based testing to improve drug efficacy and safety.</p>
<div class="lb-trans"><p>/PRNewswire/ -- 根據 Mordor Intelligence 的報告，全球伴隨診斷市場在 2025 年的估值為 87 億美元，預計到 2030 年將超過 156.2 億美元，預測期內（2025–2030 年）年均增長率為 12.42%。市場主要受精準醫療在腫瘤學和罕見疾病中的應用增長，以及基於生物標誌物的檢測需求增加的推動，以提高藥物的有效性和安全性。</p>
</div><p><strong>Regional Segment Insights</strong></p>
<div class="lb-trans"><p><strong>區域細分洞察</strong></p>
</div><p><strong>North America</strong> continues to dominate the companion diagnostics market, supported by a robust pharmaceutical pipeline, favorable reimbursement policies, and early adoption of molecular testing technologies. The region's regulatory clarity from the FDA for co-development of drugs and diagnostics has also streamlined commercialization pathways.</p>
<div class="lb-trans"><p><strong>北美</strong> 繼續主導伴隨診斷市場，得益於強大的製藥管道、良好的報銷政策以及分子檢測技術的早期採用。該地區 FDA 對藥物和診斷共同開發的監管明確性也簡化了商業化路徑。</p>
</div><p><strong>Asia-Pacific</strong> is emerging as the fastest-growing region, driven by an increasing cancer burden, expansion of genetic testing services, and the rapid development of localized diagnostic solutions in China, Japan, and India. National initiatives to integrate precision medicine into healthcare systems are further strengthening regional demand.</p>
<div class="lb-trans"><p><strong>亞太地區</strong> 正在成為增長最快的地區，受癌症負擔增加、基因檢測服務擴展以及中國、日本和印度本地化診斷解決方案快速發展的推動。國家層面的精準醫療整合到醫療系統的倡議進一步增強了區域需求。</p>
</div><p><strong>Major Trends Shaping Market Dynamics</strong></p>
<div class="lb-trans"><p><strong>塑造市場動態的主要趨勢</strong></p>
</div><p><strong>Rising Demand for Precision and Targeted Therapies</strong></p>
<div class="lb-trans"><p><strong>對精準和靶向療法的需求上升</strong></p>
</div><p>The growing emphasis on personalized medicine is reshaping treatment paradigms. Pharmaceutical companies increasingly rely on companion diagnostics to identify patient subgroups based on genetic or molecular profiles. This trend is particularly evident in oncology, where companion diagnostics guide the use of targeted therapies such as EGFR, HER2, and PD-L1 inhibitors.</p>
<div class="lb-trans"><p>對個性化醫療的日益重視正在重塑治療範式。製藥公司越來越依賴伴隨診斷來根據基因或分子特徵識別患者亞組。這一趨勢在腫瘤學中尤為明顯，伴隨診斷指導靶向療法的使用，如 EGFR、HER2 和 PD-L1 抑制劑。</p>
</div><p><strong>Integration of Next-Generation Sequencing (NGS) Technologies</strong></p>
<div class="lb-trans"><p><strong>下一代測序（NGS）技術的整合</strong></p>
</div><p>The use of NGS-based testing platforms is transforming how we discover biomarkers and perform multiplex testing. By enabling comprehensive genomic profiling across multiple mutations, NGS helps reduce both turnaround time and cost per sample. This technology is also moving beyond oncology, finding new applications in infectious diseases, neurology, and cardiovascular research.</p>
<div class="lb-trans"><p>基於 NGS 的檢測平台正在改變我們發現生物標誌物和進行多重檢測的方式。通過實現對多種突變的全面基因組分析，NGS 有助於減少週轉時間和每個樣本的成本。這項技術也正在超越腫瘤學，在傳染病、神經學和心血管研究中找到新的應用。</p>
</div><p><strong>Strategic Collaborations Between Pharma and Diagnostic Developers</strong></p>
<div class="lb-trans"><p><strong>製藥公司與診斷開發商之間的戰略合作</strong></p>
</div><p>Pharmaceutical and diagnostic firms are increasingly forming strategic alliances to co-develop companion diagnostics alongside drug pipelines. These collaborations help align regulatory submissions and accelerate market entry timelines. Additionally, the integration of AI and bioinformatics tools is improving the interpretation of complex genomic data, supporting faster clinical decision-making.</p>
<div class="lb-trans"><p>製藥和診斷公司越來越多地形成戰略聯盟，以共同開發伴隨診斷與藥物管道。這些合作有助於協調監管提交，加快市場進入時間。此外，AI 和生物信息學工具的整合正在改善複雜基因組數據的解讀，支持更快的臨牀決策。</p>
</div><p><strong>Comprehensive Segmental Overview</strong></p>
<div class="lb-trans"><p><strong>綜合細分概述</strong></p>
</div><p><strong>By Technology</strong></p>
<div class="lb-trans"><p><strong>按技術</strong></p>
</div><ul>
<li>Polymerase Chain Reaction (PCR)</li>
<li>Immunohistochemistry (IHC)</li>
<li>Real-Time PCR (RT-PCR)</li>
<li>In Situ Hybridization (ISH)</li>
<li>Next-Generation Sequencing (NGS)</li>
<li>Other Technologies</li>
</ul>
<div class="lb-trans"><ul>
<li>聚合酶鏈反應（PCR）</li>
<li>免疫組化（IHC）</li>
<li>實時 PCR（RT-PCR）</li>
<li>原位雜交（ISH）</li>
<li>下一代測序（NGS）</li>
<li>其他技術</li>
</ul>
</div><p><strong>By Indication</strong></p>
<div class="lb-trans"><p><strong>按適應症</strong></p>
</div><ul>
<li>Lung Cancer</li>
<li>Breast Cancer</li>
<li>Colorectal Cancer</li>
<li>Leukemia</li>
<li>Melanoma</li>
<li>Gastric Cancer</li>
<li>Prostate Cancer</li>
<li>Other Indications</li>
</ul>
<div class="lb-trans"><ul>
<li>肺癌</li>
<li>乳腺癌</li>
<li>結直腸癌</li>
<li>白血病</li>
<li>黑色素瘤</li>
<li>胃癌</li>
<li>前列腺癌</li>
<li>其他適應症</li>
</ul>
</div><p><strong>By Product &amp; Service</strong></p>
<div class="lb-trans"><p><strong>按產品和服務</strong></p>
</div><ul>
<li>Assays &amp; Kits</li>
<li>Instruments &amp; Analyzers</li>
<li>Software &amp; Services</li>
</ul>
<div class="lb-trans"><ul>
<li>檢測和試劑盒</li>
<li>儀器和分析儀</li>
<li>軟件和服務</li>
</ul>
</div><p><strong>By Sample Type</strong></p>
<div class="lb-trans"><p><strong>按樣本類型</strong></p>
</div><ul>
<li>Tissue Biopsy</li>
<li>Liquid Biopsy</li>
<li>Cytology Smears</li>
</ul>
<div class="lb-trans"><ul>
<li>組織活檢</li>
<li>液體活檢</li>
<li>細胞學塗片</li>
</ul>
</div><p><strong>By End User</strong></p>
<div class="lb-trans"><p><strong>按最終用户</strong></p>
</div><ul>
<li>Pharmaceutical &amp; Biotechnology Companies</li>
<li>Clinical Reference Laboratories</li>
<li>Contract Research Organizations (CROs)</li>
<li>Hospitals &amp; Cancer Centers</li>
</ul>
<div class="lb-trans"><ul>
<li>製藥和生物技術公司</li>
<li>臨牀參考實驗室</li>
<li>合同研究組織（CRO）</li>
<li>醫院和癌症中心</li>
</ul>
</div><p><strong>By Geography</strong></p>
<div class="lb-trans"><p><strong>按地區</strong></p>
</div><ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>Middle East &amp; Africa</li>
<li>South America</li>
</ul>
<div class="lb-trans"><ul>
<li>北美</li>
<li>歐洲</li>
<li>亞太地區</li>
<li>中東和非洲</li>
<li>南美</li>
</ul>
</div><p><strong>For a full breakdown of market size, segmentation data, and competitive intelligence, access the details of the Mordor Intelligence report:</strong></p>
<div class="lb-trans"><p><strong>有關市場規模、細分數據和競爭情報的完整信息，請訪問 Mordor Intelligence 報告的詳細信息：</strong></p>
</div><p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
<div class="lb-trans"><p>https://www.mordorintelligence.com/industry-reports/companion-diagnostics-market?utm_source=prnewswire</p>
</div><p><strong>Strategic Market Landscape</strong></p>
<div class="lb-trans"><p><strong>戰略市場格局</strong></p>
</div><p>The companion diagnostics market is moderately consolidated, with global diagnostics manufacturers, biotechnology companies, and technology providers actively advancing co-development partnerships and multiplex testing solutions. Market leaders focus on expanding companion tests across multiple cancer indications and investing in regulatory-approved NGS panels.</p>
<div class="lb-trans"><p>伴隨診斷市場適度集中，全球診斷製造商、生物技術公司和技術提供商積極推進共同開發合作伙伴關係和多重檢測解決方案。市場領導者專注於在多個癌症適應症中擴展伴隨檢測，並投資於獲得監管批准的 NGS 面板。</p>
</div><p><strong>Leading Companion Diagnostics Companies</strong></p>
<div class="lb-trans"><p><strong>領先的伴隨診斷公司</strong></p>
</div><ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
<div class="lb-trans"><ul>
<li>Qiagen NV</li>
<li>Agilent Technologies Inc.</li>
<li>Abbott</li>
<li>bioMérieux</li>
<li>F. Hoffmann-La Roche Ltd</li>
</ul>
</div><p><strong>Check out related reports published by Mordor Intelligence:</strong></p>
<div class="lb-trans"><p><strong>查看 Mordor Intelligence 發佈的相關報告：</strong></p>
</div><p><strong>Oncology Molecular Diagnostics Market</strong>: The Oncology Molecular Diagnostics Market Report is Segmented by Product Type (Instrument), Technology (Polymerase Chain Reaction), Cancer Type (Breast Cancer), Sample Type (Tissue Biopsy, and More), End User (Hospitals), and Geography (North America, Europe, Asia-Pacific, Middle East &amp; Africa, South America).</p>
<div class="lb-trans"><p><strong>腫瘤分子診斷市場</strong>：腫瘤分子診斷市場報告按產品類型（儀器）、技術（聚合酶鏈反應）、癌症類型（乳腺癌）、樣本類型（組織活檢等）、最終用户（醫院）和地區（北美、歐洲、亞太地區、中東和非洲、南美）進行細分。</p>
</div><p>Illumina, QIAGEN, Roche, Thermo Fisher Scientific and Danaher are the major companies operating in this market.</p>
<div class="lb-trans"><p>Illumina、QIAGEN、Roche、Thermo Fisher Scientific 和 Danaher 是該市場的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Oncology Molecular Diagnostics</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>瞭解更多活躍於</strong> <strong>腫瘤分子診斷</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/global-oncology-molecular-diagnostics-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>Companion Animal Diagnostic Market</strong>: The Companion Animal Diagnostics Market report segments the industry into By Animals (Cats, Dogs, Other Animals), By Application (Bacteriology, Parasitology, Clinical Pathology, Other Applications), By Technology (Immunodiagnostic Tests, Molecular Diagnostics, Diagnostic Imaging, Other Diagnostics), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).</p>
<div class="lb-trans"><p><strong>伴隨動物診斷市場</strong>：伴隨動物診斷市場報告將行業細分為按動物（貓、狗、其他動物）、按應用（細菌學、寄生蟲學、臨牀病理學、其他應用）、按技術（免疫診斷測試、分子診斷、診斷成像、其他診斷）和地區（北美、歐洲、亞太地區、中東和非洲、南美）。</p>
</div><p>Heska, Neogen, Zoetis, IDEXX and Innovative Diagnostics are the major companies operating in this market.</p>
<div class="lb-trans"><p>Heska、Neogen、Zoetis、IDEXX 和 Innovative Diagnostics 是該市場的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Companion Animal Diagnostic</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>瞭解更多活躍於</strong> <strong>伴隨動物診斷</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/companion-animal-diagnostic-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>Anatomic Pathology Market</strong>: The Anatomic Pathology Market Report is Segmented by Product &amp; Services (Instruments, Consumables, and Services), Application (Disease Diagnosis, Drug Discovery &amp; Development, and Other Applications), End User (Hospitals, Diagnostic Laboratories), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America).</p>
<div class="lb-trans"><p><strong>解剖病理市場</strong>：解剖病理市場報告按產品和服務（儀器、耗材和服務）、應用（疾病診斷、藥物發現與開發及其他應用）、最終用户（醫院、診斷實驗室）、地區（北美、歐洲、亞太地區、中東和非洲、南美）進行細分。</p>
</div><p>Thermo Fisher Scientific, Quest Diagnostics, Roche, LabCorp and Agilent Technologies are the major companies operating in this market.</p>
<div class="lb-trans"><p>賽默飛世爾科技、Quest Diagnostics、羅氏、LabCorp 和安捷倫科技是該市場的主要公司。</p>
</div><p><strong>Read more about companies active in</strong> <strong>Anatomic Pathology</strong> <strong>:</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
<div class="lb-trans"><p><strong>瞭解更多關於活躍於</strong> <strong>解剖病理學</strong> <strong>的公司：</strong> <strong>https://www.mordorintelligence.com/industry-reports/anatomic-pathology-market/companies?utm_source=prnewswire</strong></p>
</div><p><strong>About Mordor</strong> <strong>Intelligence:</strong></p>
<div class="lb-trans"><p><strong>關於 Mordor Intelligence：</strong></p>
</div><p>Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.</p>
<div class="lb-trans"><p>Mordor Intelligence 是一家值得信賴的合作伙伴，為尋求全面和可操作市場情報的企業提供服務。我們的全球覆蓋、專業團隊和量身定製的解決方案使組織和個人能夠做出明智的決策，駕馭複雜的市場，實現戰略目標。</p>
</div><p>With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace &amp; defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals &amp; materials, consumer goods &amp; services, electronics, energy &amp; power, financial services, food &amp; beverages, healthcare, hospitality &amp; tourism, information &amp; communications technology, investment opportunities, and logistics.</p>
<div class="lb-trans"><p>Mordor Intelligence 擁有超過 550 名領域專家和遍佈 150 多個國家的現場專家，對全球商業環境有獨特的理解。這種專業知識轉化為涵蓋航空航天與國防、農業、動物營養與健康、自動化、汽車、化學與材料、消費品與服務、電子、能源與電力、金融服務、食品與飲料、醫療保健、酒店與旅遊、信息與通信技術、投資機會和物流等廣泛行業的綜合性綜合和定製研究報告。</p>
</div><p><strong>For any inquiries, please contact:</strong></p>
<div class="lb-trans"><p><strong>如有任何諮詢，請聯繫：</strong></p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>https://www.mordorintelligence.com/contact-us</p>
<div class="lb-trans"><p>https://www.mordorintelligence.com/contact-us</p>
</div><p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
<div class="lb-trans"><p>Logo: https://mma.prnewswire.com/media/2746908/Mordor_Intelligence_Logo.jpg</p>
</div><p>SOURCE Mordor Intelligence Private Limited</p>
<div class="lb-trans"><p>來源：Mordor Intelligence Private Limited</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTA1Jk5ld3NJdGVtSWQ9SU8xNjI3MSZUcmFuc21pc3Npb25fSWQ9MjAyNTExMDUwNTAxUFJfTkVXU19VU1BSX19fX19JTzE2Mjcx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=IO16271&amp;Transmission_Id=202511050501PR_NEWS_USPR_____IO16271&amp;DateId=20251105"/></p>

Mordor Intelligence 表示，伴隨診斷市場預計到 2030 年將達到 156 億美元，年均複合增長率為 12.4%